● Recruiting

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Condition: Advanced Esophageal Squamous Cell Carcinoma · Sponsor: Shanghai Junshi Bioscience Co., Ltd.

PhasePhase 2

Planned participants280

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This study is an open-label, multi-center phase II clinical trial aimed to evaluat the safety and preliminary efficacy of JS212 combination therapy in patients with advanced esophageal squamous cell carcinoma (ESCC).

This description comes directly from the study's public registry record.

Talk to the study team

Chengbo Jia · +8618547265054 · chengbo_jia@junpharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Hospital of Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07484724